NeoGenomics stockholders approve 5 million share increase to equity incentive plan
At its May 21, 2026 annual meeting, NeoGenomics stockholders elected nine directors, approved a 5,000,000-share increase to the 2023 Equity Incentive Plan, approved an advisory vote on executive pay, and ratified Deloitte & Touche LLP as independent registered public accountant. The plan amendment increases the number of shares authorized for issuance under the plan, which the company's board had approved subject to stockholder approval.
Key points
- Shares present or represented at the May 21, 2026 meeting totaled 116,630,120, about 89.61% of outstanding voting stock as of the March 23, 2026 record date.
- Equity plan amendment approved with 108,010,493 votes for (97.90% of votes cast) and 2,308,922 against.
- Advisory approval of named executive officer compensation received 91,781,833 votes for and 18,534,236 against.
- Deloitte & Touche LLP ratified with 116,103,093 votes for and 494,869 against; all nine director nominees were elected.
The filing
Written by AI on Nov 8, 2026, 6:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 22, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.